Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles from the last 90 days matching "phase 1"

Clinical trialUNITERAREApr 3

New Recruiting Trial: Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Researchers are testing a new drug called Xaluritamig to treat Ewing sarcoma, a rare bone cancer that has come back or stopped responding to previous treatments. This is an early-stage study (Phase 1) that will include children, teenagers, and adults. The study is now accepting patients and is expected to start in April 2026.

WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer with limited treatment alternatives after standard therapies fail.
→ You can act on thisEwing sarcomaRead →
Clinical trialCLINICALTRIALSMar 26

Trial Now Recruiting: A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (NCT07070232)

Researchers are testing a new experimental cancer treatment called BNT326 to see if it is safe and works well for people with advanced solid tumors (cancers that have spread or come back after treatment). The study will first test BNT326 alone, then test it combined with other experimental treatments. About 980 people will participate in this Phase 1 and Phase 2 trial.

WHY IT MATTERSThis trial is actively recruiting patients with advanced solid tumors across multiple sites, offering access to a novel immunotherapy approach from BioNTech before it becomes widely available.
→ You can act on thisAdvanced solid tumorsMetastatic cancerRecurrent cancerRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases